ArticleBritish journal of cancer2015
Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studies.
Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Overinterpretation and misreporting of prognostic factor studies in oncology: a systematic review.British journal of cancer · 2018Pooled it
- Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome.Scientific reports · 2016Trial
- Contemporary review of prognostic markers of prostate cancer from a pathologist perspective.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2025Review
- Comprehensive analysis of cholesterol metabolism-related genes in prostate cancer: integrated analysis of single-cell and bulk RNA sequencing.Discover oncology · 2025Article
- Investigation of the clinical significance of the expression of immunohistochemical biomarkers Enhancer of zeste homolog 2 and Forkhead box M1 in localized prostate cancer tissue: A Greek retrospective study.Asian journal of urology · 2025Article
- PSMA-Targeting Imprinted Nanogels for Prostate Tumor Localization and Imaging.Advanced healthcare materials · 2025Article
- Integrative single-cell and machine learning analysis predicts lactylation-driven therapy resistance in prostate cancer: a molecular docking and experiments-validated framework for treatment optimization.Frontiers in immunology · 2025Article
- Tumor associated neutrophils promote prostate cancer progression by mediating neutrophil trap secretion through PSMA1- NF-κB-HIF-1α signaling axis.Frontiers in immunology · 2025Article
- A tumour-associated macrophage-based signature for deciphering prognosis and immunotherapy response in prostate cancer.IET systems biology · 2024Article
- Evaluation of the Immunohistochemical Scoring System of CDX2 Expression as a Prognostic Biomarker in Colon Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- Critical Evaluation of Transcripts and Long Noncoding RNA Expression Levels in Prostate Cancer Following Radical Prostatectomy.Pathobiology : journal of immunopathology, molecular and cellular biology · 2023Article
- Development of a novel, clinically relevant anoikis-related gene signature to forecast prognosis in patients with prostate cancer.Frontiers in genetics · 2023Article
- Review
- Cancer-associated fibroblast-derived gene signatures predict radiotherapeutic survival in prostate cancer patients.Journal of translational medicine · 2022Article
- Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression.Scientific reports · 2022Article
- 1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model.Frontiers in medicine · 2022Article
- Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2021Article
- Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer.Frontiers in genetics · 2021Article
- Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN).Journal of the National Cancer Institute · 2020Article
- [Reports of prostate needle biopsies-what pathologists provide and urologists want].Der Urologe. Ausg. A · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment planning of localised prostate cancer remains challenging. Besides conventional parameters, a wealth of prognostic biomarkers has been proposed so far. None of which, however, have successfully been implemented in a routine setting so far. The aim of our study was to systematically verify a set of published prognostic markers for prostate cancer.
methodsFollowing an in-depth PubMed search, 28 markers were selected that have been proposed as multivariate prognostic markers for primary prostate cancer. Their prognostic validity was examined in a radical prostatectomy cohort of 238 patients with a median follow-up of 60 months and biochemical progression as endpoint of the analysis. Immunohistochemical evaluation was performed using previously published cut-off values, but allowing for optimisation if necessary. Univariate and multivariate Cox regression were used to determine the prognostic value of biomarkers included in this study.
resultsDespite the application of various cut-offs in the analysis, only four (14%) markers were verified as independently prognostic (AKT1, stromal AR, EZH2, and PSMA) for PSA relapse following radical prostatectomy.
conclusionsApparently, many immunohistochemistry-based studies on prognostic markers seem to be over-optimistic. Codes of best practice, such as the REMARK guidelines, may facilitate the performance of conclusive and transparent future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.